{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:02:51Z","timestamp":1761238971479,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ahj.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T20:42:23Z","timestamp":1649450543000},"page":"86-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial"],"prefix":"10.1016","volume":"249","author":[{"given":"Ariane Vieira Scarlatelli","family":"Macedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Gabriel Melo","family":"de Barros e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Ceccatto","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Junqueira","family":"Moll-Bernardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Mendon\u00e7a dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme D`Andr\u00e9a Saba","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Den\u00edlson Campos","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Silvestre","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Ferreira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.04.001_bib0001","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2022.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.04.001_bib0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11906-020-01057-x","article-title":"Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?","volume":"22","author":"Drager","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ahj.2022.04.001_bib0004","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u00a0314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2022.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.04.001_bib0006","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/oby.22831","article-title":"High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation","volume":"28","author":"Simonnet","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.ahj.2022.04.001_bib0008","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.04.001_bib0009","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Mahmoud","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2022.04.001_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.120.16314","article-title":"Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients","volume":"77","author":"Semenzato","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2022.04.001_bib0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/HYPERTENSIONAHA.121.17328","article-title":"Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2","volume":"78","author":"Singh","year":"2021","journal-title":"Hypertens"},{"key":"10.1016\/j.ahj.2022.04.001_bib0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2020.05.002","article-title":"Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"226","author":"Lopes","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2022.04.001_bib0013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"year":"2022","series-title":"Centers for Disease Control and Prevention","key":"10.1016\/j.ahj.2022.04.001_bib0014"},{"key":"10.1016\/j.ahj.2022.04.001_bib0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","article-title":"Mild or moderate COVID-19","volume":"383","author":"Gandhi","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2022.04.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235248","article-title":"Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens","volume":"15","author":"Bravi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2022.04.001_bib0018","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.04.001_bib0019","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin\u2013angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ahj.2022.04.001_bib0020","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ahj.2022.04.001_bib0021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11906-008-0076-0","article-title":"Pharmacologic modulation of ACE2 expression","volume":"10","author":"Soler","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ahj.2022.04.001_bib0022","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11427-015-4814-7","article-title":"Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse","volume":"58","author":"Yan","year":"2015","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.ahj.2022.04.001_bib0023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2022.04.001_bib0024","doi-asserted-by":"crossref","first-page":"L325","DOI":"10.1152\/ajplung.00189.2020","article-title":"Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury","volume":"319","author":"Sarzani","year":"2020","journal-title":"Am J Physiola Lung Cell Mol Physiol"},{"key":"10.1016\/j.ahj.2022.04.001_bib0025","doi-asserted-by":"crossref","first-page":"e57278","DOI":"10.7554\/eLife.57278","article-title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","volume":"9","author":"Rossi","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ahj.2022.04.001_bib0026","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/jch.14011","article-title":"Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol","volume":"22","author":"Cohen","year":"2020","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ahj.2022.04.001_bib0027","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","article-title":"Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial","volume":"9","author":"Bauer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ahj.2022.04.001_bib0028","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1681\/ASN.2020050667","article-title":"Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19","volume":"31","author":"Wysocki","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2022.04.001_bib0029","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1681\/ASN.2020050667","article-title":"Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19","volume":"31","author":"Wysocki","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2022.04.001_bib0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ahj.2022.04.001_bib0031","first-page":"1","article-title":"Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with\/without hypertension","author":"Wang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.ahj.2022.04.001_bib0032","doi-asserted-by":"crossref","unstructured":"Mancia G. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. Cardiovasc Res 2020;116:e198-e199.","DOI":"10.1093\/cvr\/cvaa325"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:08:41Z","timestamp":1757570921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"alternative-id":["S0002870322000679"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.04.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}